Net Cash Provided by (Used in) Financing Activities in USD of Avalo Therapeutics, Inc. from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Avalo Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2015 to Q1 2025.
  • Avalo Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $0.000, a 100% decline year-over-year.
  • Avalo Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $176M, a 602% increase from 2023.
  • Avalo Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $25M.
  • Avalo Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$14.7M, a 114% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Avalo Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $0 -$109M -100% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q1 2024 $109M +$94.9M +690% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q1 2023 $13.7M +$13.7M Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-07-11
Q1 2022 $0 -$37.8M -100% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q1 2021 $37.8M +$28.7M +316% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $9.1M +$281K +3.19% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q1 2019 $8.82M +$8.45M +2326% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $363K +$242K +200% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 $121K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11

Avalo Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $176M +$151M +602% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-20
2023 $25M +$39.7M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-20
2022 -$14.7M -$121M -114% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 $107M +$62M +138% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
2020 $44.8M +$32.2M +257% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-02
2019 $12.6M +$2.16M +20.7% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-08
2018 $10.4M +$6.67M +178% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-11
2017 $3.74M +$5.16M Jan 1, 2017 Dec 31, 2017 10-K 2019-03-18
2016 -$1.43M -$21M -107% Jan 1, 2016 Dec 31, 2016 10-K 2018-04-02
2015 $19.6M Jan 1, 2015 Dec 31, 2015 10-K 2018-04-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.